Spruce Biosciences, Inc. (SPRB)
OTCMKTS
· Delayed Price · Currency is USD
0.0730
+0.0003 (0.41%)
Jun 18, 2025, 1:40 PM EDT
Spruce Biosciences Revenue
Spruce Biosciences had revenue of $2.91M in the twelve months ending March 31, 2025, down -71.27% year-over-year. In the year 2024, Spruce Biosciences had annual revenue of $4.91M, down -51.32%.
Revenue (ttm)
2.91M
Revenue Growth
-71.27%
P/S Ratio
1.04
Revenue / Employee
145.45K
Employees
21
Market Cap
3.03M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Elite Pharmaceuticals | 70.00M |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Glass House Brands | 215.62M |
Silence Therapeutics | 27.70M |
Spruce Biosciences News
- 8 days ago - Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market - Seeking Alpha
- 8 days ago - Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market - Business Wire
- 6 weeks ago - Spruce Biosciences GAAP EPS of -$0.32 misses by $0.05 - Seeking Alpha
- 6 weeks ago - Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - Business Wire
- 2 months ago - Spruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript) - Seeking Alpha
- 2 months ago - Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
- 6 months ago - Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Benzinga
- 6 months ago - Spruce Biosciences to wind down investment for genetic disorder drug - Reuters